2023, Número 2
<< Anterior Siguiente >>
Arch Neurocien 2023; 28 (2)
The effects of memantine and mk 801 on nmda receptor switching 2b and 2a subunits in hippocampal cell culture
Uribe E, Sanchez-Mendoza E
Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 20-27
Archivo PDF: 286.83 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Rapoport JL, Addington AM, Frangou S, Psych MR. Theneurodevelopmental model of schizophrenia: update 2005. MolPsychiatry. 2005; 10(5):434-49. doi: 10.1038/sj.mp.4001642
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL,Perkins DO, et al. Practice guideline for the treatment of patients withschizophrenia, second edition. Am J Psychiatry. 2005;161( S2):1-56.
Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M,et al. Redox dysregulation, neuroinflammation, and NMDA receptorhypofunction: A “central hub” in schizophrenia pathophysiology?Schizophr Res. 2016; 176(1):41-51. doi: 10.1016/j.schres.2014.06.021
Liu XB, Murray KD, Jones EG. Switching of NMDA receptor 2A and2B subunits at thalamic and cortical synapses during early postnataldevelopment. J Neurosci. 2004; 24(40):8885-95. doi: 10.1523/JNEUROSCI.2476-04.2004
Liu H, Li Y, Wang Y, Wang X, An X, Wang S, et al. The distinct role ofNR2B subunit in the enhancement of visual plasticity in adulthood.Mol Brain. 2015; 8:49. doi: 10.1186/s13041-015-0141-y
Monaco SA, Gulchina Y, Gao WJ. NR2B subunit in the prefrontalcortex: A double-edged sword for working memory function andpsychiatric disorders. Neurosci Biobehav Rev. 2015; 56: 127-38.doi: 10.1016/j.neubiorev.2015.06.022
Philpot BD, Cho KK, Bear MF. Obligatory role of NR2A formetaplasticity in visual cortex. Neuron. 2007; 53(4):495-502. doi:10.1016/j.neuron.2007.01.027
Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction,parvalbumin-positive neurons, and cortical gamma oscillations inschizophrenia. Schizophr Bull. 2012; 38(5):950-7. doi: 10.1093/schbul/sbs010
Marballi KK, Gallitano AL. Immediate early genes anchor abiological pathway of proteins required for memory formation, longtermdepression and risk for schizophrenia. Front Behav Neurosci.2018; 12:23. doi: 10.3389/fnbeh.2018.00023
Uribe E, Fernández L. Effects of neonatal administration of memantineon hippocampal asymmetry and working memory impairmentinduced by early maternal deprivation in rats. Neurophysiology.2019; 51:97-106. doi: 10.1007/s11062-019-09799-4
Behrendt RP. Dysregulation of thalamic sensory “transmission”in schizophrenia: neurochemical vulnerability to hallucinations.J Psychopharmacol (Oxford). 2006; 20(3):356-72. doi:10.1177/0269881105057696
Hoffmann H, Gremme T, Hatt H, Gottmann K. Synaptic activitydependentdevelopmental regulation of NMDA receptor subunitexpression in cultured neocortical neurons. J Neurochem. 2000;75(4):1590-9. doi: 10.1046/j.1471-4159.2000.0751590.x
Song X, Jensen MØ, Jogini V, Stein RA, Lee CH, Mchaourab HS,et al. Mechanism of NMDA receptor channel block by MK-801and memantine. Nature. 2018; 556(7702):515-9. doi: 10.1038/s41586-018-0039-9
Uribe E, Sánchez-Mendoza E, Nieves N, Merchor G. Neonataladministration of memantine enhances social cognition in adultrats subjected to early maternal deprivation. Exp neurobiol. 2016;25(6):328-32. doi: 10.5607/en.2016.25.6.328
Uribe E, Fernández L, Pacheco D, Fernandez L, Nayadoleni N,Eblen-Zajjur A. Administration of memantine reverses behavioral,histological, and electrophysiological abnormalities in rats subjectedto early maternal deprivation. J Neural Transm (Vienna). 2019;126(6):759-70. doi: 10.1007/s00702-019-02007-x
Hirayama M, Kuriyama M. MK-801 is cytotoxic to microglia in vitroand its cytotoxicity is attenuated by glutamate, other excitotoxicagents and atropine. Possible presence of glutamate receptor andmuscarinic receptor on microglia. Brain Res. 2001; 897(1-2):204-206. doi:10.1016/s0006-8993(01)02114-x
Emnett CM, Eisenman LN, Taylor AM, Izumi Y, Zorumski CF,Mennerick S. Indistinguishable synaptic pharmacodynamics of theN-methyl-D-aspartate receptor channel blockers memantine andketamine. Mol Pharmacol. 2013; 84(6):935-47. doi: 10.1124/mol.113.089334
Chen HS, Lipton SA. Pharmacological implications of two distinctmechanisms of interaction of memantine with N-methyl-D-aspartategatedchannels. J Pharmacol Exp Ther. 2005; 314(3):961-71. doi:10.1124/jpet.105.085142
Sans N, Petralia RS, Wang YX, Blahos J 2nd, Hell JW, WentholdRJ. A developmental change in NMDA receptor-associated proteinsat hippocampal synapses. J Neurosci. 2000; 20(3):1260-71. doi:10.1523/JNEUROSCI.20-03-01260.2000
Frantseva MV, Fitzgerald PB, Chen R, Möller B, Daigle M, DaskalakisZJ. Evidence for impaired long-term potentiation in schizophreniaand its relationship to motor skill learning. Cereb Cortex.2008;18(5):990-6. doi: 10.1093/cercor/bhm151
Xi D, Zhang W, Wang HX, Stradtman GG, Gao WJ. Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptorsubunits in parvalbumin-containing interneurons in young adult ratprefrontal cortex. Int J Neuropsychopharmacol. 2009;12(10):1395-1408. doi: 10.1017/S146114570900042X
Ewald RC, Van Keuren-Jensen KR, Aizenman CD, Cline HT. Roles ofNR2A and NR2B in the development of dendritic arbor morphologyin vivo. J Neurosci. 2008; 28(4):850-61. doi: 10.1523/JNEUROSCI.5078-07.2008
Ganguly P, Holland FH, Brenhouse HC. Functional uncouplingNMDAR NR2A subunit from PSD-95 in the prefrontal cortex: effectson behavioral dysfunction and parvalbumin loss after early-life stress[published correction appears in Neuropsychopharmacology. 2016;41(4):1188]. Neuropsychopharmacology. 2015; 40(12):2666-75.doi: 10.1038/npp.2015.134
Schoonover KE, McCollum LA, Roberts RC. Protein markers ofneurotransmitter synthesis and release in postmortem schizophreniasubstantia nigra. Neuropsychopharmacology. 2017; 42(2):540-50.doi: 10.1038/npp.2016.164
Castillo MA, Ghose S, Tamminga CA, Ulery-Reynolds PG.Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontalcortex. Biol Psychiatry. 2010; 67(3):208-16. doi: 10.1016/j.biopsych.2009.07.029
26. Sanchez EH, Camblor S, Martins L, Dzyubenko E, Fleischer M,Carvalho T, et al. Compromised hippocampal neuroplasticity inthe interferon-α and toll-like receptor-3 activation-induced mousedepression model. Mol Neurobiol. 2020; 57(7):3171-82. doi:10.1007/s12035-020-01927-0
Bagasrawala I, Memi F, V Radonjic N, Zecevic N. N-methyl d-aspartatereceptor expression patterns in the human fetal cerebral cortex. CerebCortex. 2017; 27(11):5041-53. doi: 10.1093/cercor/bhw289
Roceri M, Hendriks W, Racagni G, Ellenbroek BA, Riva MA. Earlymaternal deprivation reduces the expression of BDNF and NMDAreceptor subunits in rat hippocampus. Mol Psychiatry. 2002;7(6):609-16. doi: 10.1038/sj.mp.4001036
Yu W, Zhu M, Fang H, Zhou J, Ye L, Bian W, et al. Risperidonereverses the downregulation of BDNF in hippocampal neurons andMK801-induced cognitive impairment in rats. Front Behav Neurosci.2019; 13:163. doi: 10.3389/fnbeh.2019.00163
Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, RiedererP, et al. Memantine upregulates BDNF and prevents dopaminedeficits in SIV-infected macaques: a novel pharmacological actionof memantine. Neuropsychopharmacology. 2008; 33(9):2228-36.doi: 10.1038/sj.npp.1301615
Amidfar M, Kim YK, Wiborg O. Effectiveness of memantine ondepression-like behavior, memory deficits and brain mRNA levelsof BDNF and TrkB in rats subjected to repeated unpredictablestress. Pharmacol Rep. 2018; 70(3):600-6. doi: 10.1016/j.pharep.2017.12.007
Folch J, Busquets O, Ettcheto M, Sánchez-López E, Castro-TorresRD, Verdaguer E, et al. Memantine for the treatment of dementia:a review on its current and future applications. J Alzheimers Dis.2018;62(3):1223-40. doi:10.3233/JAD-170672
Eyjolfsson EM, Brenner E, Kondziella D, Sonnewald U. Repeatedinjection of MK801: an animal model of schizophrenia? NeurochemInt. 2006; 48(6-7):541-6. doi: 10.1016/j.neuint.2005.11.019
Daya RP, Bhandari JK, Hui PA, Tian Y, Farncombe T, Mishra RK.Effects of MK-801 treatment across several pre-clinical analysesincluding a novel assessment of brain metabolic function utilizingPET and CT fused imaging in live rats. Neuropharmacology. 2014;77:325-33. doi: 10.1016/j.neuropharm.2013.10.001.